Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-669899f699-7tmb6 Total loading time: 0 Render date: 2025-04-25T14:21:43.192Z Has data issue: false hasContentIssue false

12 - Botulinum toxin in the management of back and neck pain

Published online by Cambridge University Press:  02 December 2009

By
Áine Carroll
Edited by
Anthony B. Ward  and
Michael P. Barnes
Áine Carroll
Affiliation:
The National Rehabilitation Hospital, Dun Laoghaire, Co. Dublin, Ireland
Anthony B. Ward
Affiliation:
University Hospital of North Staffordshire
Michael P. Barnes
Affiliation:
Hunters Moor Regional Neurological Rehabilitation Centre
Get access

Summary

Introduction

Musculoskeletal problems are the most common cause of disability in the UK.

Most literature regarding spinal pain concentrates on acute or chronic low back pain rather than neck and thoracic spine pain. Pain from the spinal region, e.g. neck and the low back, is a major health problem in the industrialized world. Although spinal pain is common, its aetiology remains obscure. The association between symptoms, imaging results and anatomical or physiological changes, is weak. Despite often exhaustive investigations, up to 85 per cent of patients with low back pain, will find no definite causal diagnosis. Similar findings apply to neck and shoulder pain.

The most common site of spinal pain is the lower back. Neck pain appears to be almost as frequent, while thoracic pain is less prevalent. Neck symptoms are often poorly differentiated from pain in the shoulder region and the two are therefore often combined. Low back pain and neck pain frequently occur together.

In developed countries, in excess of 70 per cent of the population can expect to experience back pain at some time in their lives. Each year, 15–45 per cent of adults suffer from back pain, and one in 20 people present to a hospital with a new episode. Low back pain presents most commonly between the ages of 35 and 55 years. The vast majority of patients suffer from pain, which is usually moderate or severe and is generally benign.

Type
Chapter
Information
Clinical Uses of Botulinum Toxins , pp. 243 - 261
Publisher: Cambridge University Press
Print publication year: 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

Health Survey for England 2001 – Disability: A survey carried out on behalf of the Department of Health, Edited by Madhavi Bajekal, Paola Primatesta and Gillian Prior, Joint Health Surveys Unit National Centre for Social Research, Department of Epidemiology and Public Health at the Royal Free and University College Medical School. Published by The Stationery Office (ISBN 0-11-322601-2).
Waddell, G. (1996). Low back pain: a twentieth century health care enigma. Spine, 21, 2820–5.CrossRefGoogle ScholarPubMed
Andersson, G. B. J. (1997). The epidemiology of spinal disorders. In Frymoyer, J. W., ed., The Adult Spine: Principles and Practice, 2nd edn. Philadelphia: Lippincott-Raven Publishers, pp. 93–141.Google Scholar
Linton, S., Hellsing, A.-L. and Hallden, K. (1998). A population-based study of spinal pain among 35–45-year-old individuals: prevalence, sick leave and health care use. Spine, 23, 1457–63.CrossRefGoogle ScholarPubMed
Deyo, R. A. and Weinstein, J. N. (2001). Low-back pain. New England Journal of Medicine, 344, 363–70.CrossRefGoogle ScholarPubMed
Mäkelä, M., Heliövaara, M., Sievers, K., Impivaara, O., Knekt, P. and Aromaa, A. (1991). Prevalence, determinants, and consequences of chronic neck pain in Finland. American Journal of Epidemiology, 134, 1356–67.CrossRefGoogle ScholarPubMed
Webb, R., Brammah, T., Lunt, M., Urwin, M., Allison, T. and Symmons, D. (2003). Prevalence and predictors of intense, chronic and disabling neck and back pain in the UK general population. Spine, 28(11), 1195–202.CrossRefGoogle ScholarPubMed
Back Pain. Report of a CSAG Committee on Back Pain, 1994, HMSO.
Epidemiology Review: The Epidemiology and Cost of Back Pain. Clinical Standards Advisory Group, 1994, HMSO.
RCGP Clinical Guidelines for the Management of Acute Low Back Pain Review Date: December 2001.
Koes, B. W., Tulder, M. W., Ostelo, R., Burton, K. and Waddell, G. (2001). Clinical guidelines for the management of low pain in primary care: an international comparison. Spine, 26(22), 2504–14.CrossRefGoogle Scholar
Deyo, R. A., Diehl, A. K. and Rosenthal, M. (1986). How many days of bed rest for acute low back pain?New England Journal of Medicine, 315, 1064–70.CrossRefGoogle ScholarPubMed
Hoogen, H. J. M., Koes, B. W., Eijk, K. T. M.et al. (1998). On the course of low back pain in general practice: a one year follow up study. Annals of the Rheumatic Diseases, 57, 13–19.CrossRefGoogle ScholarPubMed
Vroomen, P., Krom, M., Wilmink, J. T.et al. (1999). Lack of effectiveness of bed rest for sciatica. New England Journal of Medicine, 340, 418–23.CrossRefGoogle ScholarPubMed
Hagen, K. B. (2001). Bed Rest for Acute Low Back Pain and Sciatica (Cochrane Review). The Cochrane Library (Issue 2), Oxford.Google ScholarPubMed
Waddell, G., Feder, G., McIntosh, A.et al. (1999). Low Back Pain Evidence Review. London: Royal College of General Practitioners.Google Scholar
Waddell, G., Feder, G. and Lewis, M. (1997). Systematic reviews of bed rest and advice to stay active for acute low back pain. Br. J. Gen. Pract., 47(423), 647–52.Google ScholarPubMed
Waddell, G. (1999). Chiropractic for low back pain. Evidence for manipulation is stronger than that for most orthodox medical treatments. BMJ, 318(7178), 262.Google ScholarPubMed
Gilbert, J. R., Taylor, D. W., Hildebrand, A., et al. (1985). Clinical trial of common treatment for low back pain in family practice. BMJ (Clin. Res. Ed)., 66, 791–4.CrossRefGoogle Scholar
Porter, R. W. and Ralston, S. H. (1994). Pharmacological management of back pain syndromes. Drugs, 48, 189–98.CrossRefGoogle ScholarPubMed
Craen, A. J., Di Giulio, G., Lampe-Schoenmaeckers, J. E., Kessels, A. G. and Kleijnen, J. (1996). Analgesic efficacy and safety of paracetamol–codeine combinations versus paracetamol alone: a systematic review. BMJ, 313(7053), 321–5.CrossRefGoogle ScholarPubMed
Moore, A., Collins, S., Carroll, D. and McQuay, H. (1997). Paracetamol with and without codeine in acute pain: a quantitative systematic review. Pain, 70(2–3), 193–201.CrossRefGoogle ScholarPubMed
Medicines Resource (1997). Management of chronic pain in the community. Medicines Resource, 41, 159–60.
Tulder, M. W., Touray, T., Furlan, A. D., Solway, S. and Bouter, L. M. (2003). Muscle relaxants for nonspecific low back pain: a systematic review within the framework of the Cochrane collaboration. Spine, 28, 1978–92.CrossRefGoogle ScholarPubMed
Aker, P. D., Gross, A. R., Goldsmith, C. H. and Peloso, P. (1996). Conservative management of mechanical neck pain: systematic overview and meta-analysis. BMJ, 313, 1291–6.CrossRefGoogle ScholarPubMed
Tulder, M. W., Koes, B. W. and Bouter, L. M. (1997). Conservative treatment of acute and chronic non-specific low back pain: a systematic review of randomized controlled trials of the most common interventions. Spine, 22, 2128–56.CrossRefGoogle Scholar
Salerno, S. M., Browning, R. and Jackson, J. L. (2002). The effect of antidepressant treatment on chronic back pain: a meta-analysis. Archives of Internal Medicine, 162, 19–24.CrossRefGoogle ScholarPubMed
Turner, J. A. and Denny, M. C. (1993). Do antidepressant medications relieve chronic low back pain?Journal of Family Practice, 37, 545–53.Google ScholarPubMed
Fishbain, D. (2000). Evidence-based data on pain relief with antidepressants. Annals of Medicine, 32, 305–16.CrossRefGoogle ScholarPubMed
Lehmann, J. F. (1982). Therapeutic Heat and Cold. 3rd edn. Baltimore: Williams & Wilkins.Google Scholar
Beurskens, A. J., Vet, M. C., Koke, A. J., Regtop, W., Heijden, G. J., Lindeman, E. et al. (1997). Efficacy of traction for nonspecific low back pain. 12-week and 6-month results of a randomized clinical trial. Spine, 22, 2756–62.CrossRefGoogle ScholarPubMed
Herman, E., Williams, R., Stratford, P., Fargas-Babjak, A. and Trott, M. (1994). A randomized controlled trial of transcutaneous electrical nerve stimulation (CODETRON) to determine its benefits in a rehabilitation program for acute occupational low back pain. Spine, 19, 561–8.CrossRefGoogle Scholar
Tulder, M. W., Jellema, P., Poppel, M. N.et al. (2000). Lumbar supports for prevention and treatment of low back pain (Cochrane Review). The Cochrane Library (Issue 2). Oxford
Tulder, M. W., Esmail, R., Bombardier, C. and Koes, B. W. (2000). Back schools for non-specific low back pain (Cochrane Review). The Cochrane Library (Issue 2). Oxford
Tulder, M. W., Ostelo, R., Vlaeyen, J. W.et al. (2001). Behavioral treatment for chronic low back pain: a systematic review within the framework of the Cochrane Back Review Group. Spine, 26, 270–81.CrossRefGoogle ScholarPubMed
Effective Health Care Bulletin (2000). Acute and chronic low back pain. Effective Health Care, 6, 1–8.
Mathews, J. A., Mills, S. B., Jenkins, V. M.et al. (1987). Back pain and sciatica: controlled trials of manipulation, traction, sclerosant and epidural injections. British Journal of Rheumatology, 26, 416–23.CrossRefGoogle ScholarPubMed
Koes, B. W., Scholten, R. J., Mens, J. M. and Bouter, L. M. (1995). Efficacy of epidural steroid injections for low-back pain and sciatica: a systematic review of randomized clinical trials. Pain, 63, 279–88.CrossRefGoogle ScholarPubMed
Nelemans, P. J., Bie, R. A.D., Vet, H. C. W. D. and Sturmans, F. (2001). Injection therapy for subacute and chronic benign low back pain (Cochrane Review). The Cochrane Library (Issue 2). Oxford
McDonald, G. J., Lord, S. M. and Bogduk, N. (1999). Long-term follow-up of patients treated with cervical radiofrequency neurotomy for chronic neck pain. Neurosurgery, 45, 61–8.Google ScholarPubMed
Nancy, J. O. and Birkmeyer, J. N. (1999). Weinstein medical versus surgical treatment for low back pain. Evidence and Clinical Practice, Effective Clinical Practice, September/October.Google Scholar
Weber, H. (1983). Lumbar disc herniation. A controlled, prospective study with ten years of observation. Spine, 8, 131–40.CrossRefGoogle ScholarPubMed
Jens, I. B., Sorensen, R., Friis, A., Nygaard, O., Indahl, A., Keller, A., Ingebrigtsen, T., Eriksen, H., Holm, I., Koller, A. K., Riise, R. and Reikeras, O. (2003). Randomized clinical trial of lumbar instrumented fusion and cognitive intervention and exercises in patients with chronic low back pain and disc degeneration. Spine, 28(17), 1913–21.Google Scholar
Indahl, A., Velund, L. and Reikeraas, (1995). Good prognosis for low back pain when left untampered. A randomized clinical trial. Spine, 20, 473–7.CrossRefGoogle ScholarPubMed
Philip, S. K. (2002). Role of injection therapy: review of indications for trigger point injections, regional blocks, facet joint injections, and intra-articular injections. Curr. Opin. Rheumatol., 14, 52–7.Google Scholar
Foster, L., Clapp, L., Erickson, M. and Jabbari, B. (2001). Botulinum toxin A and chronic back pain: a randomized, double-blinded study. Pain Practice, 1(4), 379–80.Google Scholar
Foster, L., Clapp, L., Erickson, M. and Jabbari, B. (2001). Botulinum toxin A and chronic low back pain: a randomized, double-blind study. Neurology, 56(10), 1290–3.CrossRefGoogle ScholarPubMed
Opida, C. L. (2002). Open-label study of MyoblocTM/Neurobloc (botulinum toxin type B) in the treatment of patients with chronic low back pain. Poster 202 presented at the International Conference 2002: Basic and Therapeutic Aspect of Botulinum and Tetanus Toxins : June 9, 2002. Hannover, Germany.Google Scholar
Knusel, B., DeGryse, R., Grant, M.et al. (1998). Intramuscular injection of botulinum toxin type A (BOTOX) in chronic low back pain associated with muscle spasm. Presented at 17th Annual Scientific Meeting, American Pain Society, November 5–8, San Diego, California.Google Scholar
Acquadro, M. A. and Borodic, G. E. (1994). Treatment of myofascial pain with botulinum A toxin. Anesthesiology, 80, 705–6 (Letter).CrossRefGoogle ScholarPubMed
Alo, K. M., Yland, M. J., Kramer, D. L.et al. (1997). Botulinum toxin in the treatment of myofascial pain. Pain Clinics, 10, 107–16.Google Scholar
Grana, E. A. (1998). Treatment of chronic cervical myofascial pain with botulinum toxin. Arch. Phys. Med. Rehab., 79, 1172. Royal, M. A., Gordin, V., Huebert, J. D. et al. (1999). Botulinum toxin type A botox in the treatment of refractory myofascial pain. Abstract presented at the International Conference 1999: Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins, Orlando, FL, November 16–18, p. 73.Google Scholar
Lalli, F., Gallai, V., Tambasco, N.et al. (1999). Botulinum A toxin versus lidocaine in the treatment of myofascial pain: a double-blind randomized study. Presented at the International Conference 1999: Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins, Orlando, FL, November 16–18.Google Scholar
Porta, M. (2000). A comparative trial of botulinum toxin type A and methylprednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm. Pain, 85, 101–5.CrossRefGoogle ScholarPubMed
Nalamachu, S. (2002). Treatment with botulinum toxin type B (Myobloc™) injections in three patients with myofascial pain. Abstract presented at the AAPM 18th Annual Meeting, San Francisco, CA, February 26–March 3.Google Scholar
Smith, H., Audette, J., Dey, R.et al. (2002). Botulinum toxin type B for a patient with myofascial pain. Abstract presented at the AAPM 18th Annual Meeting, San Francisco, CA, February 26–March 3.Google Scholar
Dubin, A., Smith, H. and Tang, J. (2002). Evaluation of botulinum toxin type B (Myobloc™) injections in a patient with painful muscle spasms. Pain, 3(Suppl. 1), 11 (abstract).Google Scholar
Andres, J., Cerda-Olmedo, G., Valia, J. C., Monsalve, V., Lopez-Alarcon, and Minguez, A. (2003). Use of botulinum toxin in the treatment of chronic myofascial pain. Clinical Journal of Pain, 19(4), 269–75.CrossRefGoogle ScholarPubMed
Porta, M., Perretti, A., Gamba, M., Luccarelli, G. and Fornari, M. (1998). The rationale and results of treating muscle spasm and myofascial syndromes with botulinum toxin type A. Pain Digest, 8, 346–52.Google Scholar
Wheeler, A. H., Goolkasian, P. and Gretz, S. S. (1998). A randomized, double-blind, prospective pilot study of botulinum toxin injection for refractory, unilateral cervicothoracic, paraspinal, myofascial pain syndrome. Spine, 23, 1662–7.CrossRefGoogle ScholarPubMed
Freund, B. J. and Schwartz, M. (2000). Treatment of whiplash-associated neck pain with botulinum toxin A: a pilot study. Headache, 40, 231–6 and J. Rheum., 27, 481–4.Google Scholar
Opida, C. L. (2002). Evaluation of Myobloc™ (botulinum toxin type B) in patients with post-whiplash headaches. Abstract presented at the AAPM 18th Annual Meeting, San Francisco, CA, February 26–March 3.Google Scholar
Taqi, D., Gunyea, I., Bhakta, B.et al. (2002). Botulinum toxin type A in the treatment of refractory cervicothoracic myofascial pain. Pain, 3(Suppl. 1), 16 (abstract).Google Scholar
Taqi, D., Royal, M., Gunyea, I.et al. (2002). Botulinum toxin type B (Myobloc™) in the treatment of refractory myofascial pain. Pain, 3(Suppl. 1), 16 (abstract).Google Scholar
Schiavo, G., Rossetto, O., Santucci, A., DasGupta, B. R. and Montecucco, C. (1992). Botulinum neurotoxins are zinc proteins. Journal of Biological Chemistry, 267, 23479–83.Google ScholarPubMed
Arezzo, J. C. (2002). Possible mechanisms for the effects of botulinum toxin on pain. The Clinical Journal of Pain, 18(6), S125–S32.CrossRefGoogle ScholarPubMed
Simons, D. G., Travell, J. G. and Simons, L. S. (1999). In Travell and Simons' Myofascial Pain and Dysfunction: the Trigger Point Manual. 2nd edn. Baltimore: Williams & Wilkins.Google Scholar
Lange, D. J., Brin, M. F., Warner, C. L., Fahn, S. and Lovelace, R. E. (1987). Distant effects of local injection of botulinum toxin. Muscle and Nerve, 10, 552–5.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×